AEON Biopharma, Inc. (AEON): Nasdaq/NYSE listing notice — Priveterra Acquisition receives Nasdaq deficiency notice for MVLS below $35M; adjourns special meeting

AEON Biopharma, Inc.

Nasdaq notified that MVLS was below $35M minimum for 30 consecutive business days; 180-day cure period ends Dec 11, 2023.
Special meeting for AEON Biopharma business combination adjourned from June 15 to June 21, 2023 for more stockholder engagement.
Company may consider options to regain compliance with MVLS requirement; securities continue trading during cure period.
Proxy supplement filed; no change to record date, redemption deadline, or other proposals.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AEON Biopharma, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2), 5810(c)(3)(C)

Exact text from the filing

June 13, 2023, the Company received a notification letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that for the last 30 consecutive business days preceding the date of the Notice, the Company’s Market Value of Listed Securities (“MVLS”) has been below the minimum of $35,000,000 required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days, or until December 11, 2023, to regain compliance with the MVLS Requirement (the “Co

View on SEC.gov

Browse all listing & compliance notices →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-071656

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.